Analysts Offer Insights on Healthcare Companies: Urovant Sciences Ltd (UROV) and Palatin Technologies (PTN)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Urovant Sciences Ltd (UROV) and Palatin Technologies (PTN) with bullish sentiments.

Urovant Sciences Ltd (UROV)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urovant Sciences Ltd today and set a price target of $28. The company’s shares closed on Friday at $8.24.

Selvaraju said:

“We have valued Urovant based on a discounted cash flow (DCF)-based analysis, which ascribes a total of $1.1B to vibegron in the OAB and IBS-associated pain indications. Our probability of approval in OAB is 90%, while the probability of approval for IBS-associated pain is 50%. We have applied a 12% discount rate to all future cash flows, along with an effective tax rate of 18%. This translates into a price objective of $28.00, assuming roughly 40.6M shares outstanding as of end-calendar 1Q20.”

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 3.1% and a 33.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on Urovant Sciences Ltd is a Strong Buy with an average price target of $25.67, a 211.5% upside from current levels. In a report issued on June 14, Cowen & Co. also maintained a Buy rating on the stock with a $25 price target.

See today’s analyst top recommended stocks >>

Palatin Technologies (PTN)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies today and set a price target of $7.50. The company’s shares closed on Friday at $1.34.

Pantginis wrote:

“Valuation appears attractive based on initial addressable market size. We reiterate our Buy rating and are increasing our price target to $7.50 from $6. The drivers impacting our valuation are: (1) adjustment to base year; (2) increasing our projected chance of success for (3) increasing our projected chance of success for and Korea. Our price target is based on our clinical net present value (NPV) model, of which 83% is derived from the bremelanotide opportunity and the remainder from PL-8177 and PL-3994.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -3.1% and a 34.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Palatin Technologies with a $5.13 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts